Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases
- 15 February 2009
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (4), 1132-1135
- https://doi.org/10.1016/j.bmcl.2008.12.097
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300Circulation, 2008
- Histone acetyltransferase complexes: one size doesn't fit allNature Reviews Molecular Cell Biology, 2007
- Quinoline Derivative MC1626, a Putative GCN5 Histone Acetyltransferase (HAT) Inhibitor, Exhibits HAT-Independent Activity against Toxoplasma gondiiAntimicrobial Agents and Chemotherapy, 2007
- Histone acetyltransferase MOZ acts as a co-activator of Nrf2–MafK and induces tumour marker gene expression during hepatocarcinogenesisBiochemical Journal, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004